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REVIEW
Abstract: Beta-blockers have been shown to improve survival in patients with chronic heart
failure. The effect of different generations of beta blockers has been debated. Both metoprolol
and carvedilol have demonstrated beneficial effects in placebo-controlled trials. In The
Carvedilol Or Metoprolol European Trial (COMET) two beta blockers were compared in a
double-blind randomized matter. This is the first direct comparison between metoprolol and
carvedilol of long-term effect on survival in patients with chronic heart failure. The all-cause
mortality was significantly reduced in the favour of carvedilol. The dose and formulation of
metoprolol used in this trial has caused debate, and it has been questioned whether a similar
beta1-blockade is obtained in the two intervention groups. At this time there is an unresolved
debate as to whether carvedilol is a superior beta-blocker or whether differences in beta1-
blockade explained the results of COMET.
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Introduction Introduction Introduction Introduction Introduction
Heart failure is a growing problem with an increasing number of affected people and
with an increasing burden on society (Greenberg 2004). Much has been done to
improve survival in patients with heart failure. The first breakthrough came with the
VHEFT-1 (Vasodilator Heart Failure Trial) trial where it was demonstrated that a
combination of hydralazine and isosorbide dinitrate was able to improve survival of
patients with heart failure (Cohn et al 1986). Shortly after it was demonstrated that
angiotensin-converting enzyme (ACE) inhibitors could also improve survival (Pfeffer
et al 1992; Kober et al 1995). But the mortality remained high and the need for
further improvement was evident. The failing human heart has an increased adrenergic
drive, which mediates its adverse effect through beta1- and possibly beta2- and alpha1-
adrenergic receptors (Bristow 2000). This was the rationale for introducing beta-
blockers in the treatment of chronic heart failure.
Beta1-receptors are down-regulated in the failing heart; the beta2-receptors are
un-changed and the alpha1-receptors are increased. In patients with heart failure it
was found that 50% of the adrenergic receptors in the heart were beta1-receptors and
the rest were beta2- and alpha1-receptors (Bristow et al 1986, 1988, 1997; Bristow
1993).
Most of the myocardial damage observed in heart failure appears to be beta1-
mediated (Dorn 2002) with both pathological hypertrophy (Lowes et al 2002) as
well as apoptosis (Communal et al 1999) being mediated via the beta1-receptor.
Much myocardial damage in the failing human heart is mediated by norepinephrine
(NE). The relative potency of NE for beta1-, beta2-, and alpha1-receptors is 20:1:2
(Bristow 1997). Norepinephrine is released from presynaptic stores and stimulates
beta1-receptors preferentially (Khamssi and Brodde 1990).
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On this background it is evident that beta-blockers can
have a place in the treatment of heart failure, but it is unclear
whether beta-1 selective blockers or non-selective blockers
are preferable.
Beta-blocker treatment in heart Beta-blocker treatment in heart Beta-blocker treatment in heart Beta-blocker treatment in heart Beta-blocker treatment in heart
failure failure failure failure failure
Beta-blockers have been shown to be of clinical benefit in
patients with chronic heart failure (Greenberg 2004). The
first study was performed by Waagstein and colleagues
(1975). One patient was given alprenolol and 6 patients
received practolol (Waagstein et al 1975). They all had an
improved ventricular function due to the beta-blocker
treatment and considerations for using beta-blockers in the
treatment of heart failure began.
During the nineties an array of large randomized trials
of beta-blockers for the treatment of chronic heart failure
(CHF) were conducted. In 1990 the results from the
Xamoterol in Severe Heart Failure Trial was published
(Xamoterol 1990). Even though preliminary data had shown
that treatment with the beta1-blocker xamoterol in patients
with CHF was a safe and effective treatment, the result of
the trial was disappointing. No beneficial effect of treatment
with xamoterol was observed. In an analysis of intention-to
treat 9.1% of the patients in the xamoterol-treated group
died within the first 100 days from randomization, compared
with 3.7% in the placebo-treated group. Xamoterol has a
major intrinsic sympatomimetic effect, which is not thought
beneficial for use in patients with heart failure. The failure
of xamoterol is generally attributed to the intrinsic
sympatomimetic activity, but another important
consideration is that the treatment was initiated with a high
dose from the very start in patients with extreme risk.
In CIBIS I (The Cardiac Insufficiency Bisoprolol Study),
bisoprolol was compared with placebo in 641 patients with
CHF, New York Heart Association (NYHA) Classification
III–IV , with a follow-up period of almost 2 years. No
significant difference was seen in the rate of death (CIBIS
1994), but the study was underpowered. A few years later
bisoprolol was once again tested in the CIBIS II trial. 2647
patients were randomized to receive either bisoprolol or
placebo, and the follow-up period lasted for about 1 year
(CIBIS 1999). This time a significant reduction in all cause
mortality as well as cardiovascular death and hospitalization
for cardiovascular reasons was observed. Actually the
benefit in CIBIS I and II were identical and the differences
in significance are explained by the different sample sizes
of the studies.
The Metoprolol CR/XL Randomized Intervention Trial
in Congestive Heart Failure (MERIT-HF) with 3991 patients
enrolled, examined the effect of metoprolol in patients with
CHF, NYHA II–IV , and as for bisoprolol, metoprolol
succinate showed a favourable effect on all-cause mortality
compared with placebo (MERIT-HF 1999).
Another study was performed in a population with many
black patients, where patients with CHF, NYHA III-IV were
randomized to receive either bucindolol or placebo (BEST
2001). A non-significant difference in all-cause mortality
was observed, 15% of the patients in the group treated with
bucindolol died compared with 17% in the group treated
with placebo. The results of this trial have caused some
debate. There have been speculations that the relative
predominance of black patients influenced the results of the
trial but this speculation has not been substantiated. In a
subsequent retrospective study, it was demonstrated that
there was a subset of patients who experienced marked
sympatholysis with bucindolol (Bristow et al 2004) and who
had an increased risk of death. There has also been an
unresolved debate as to whether bucindolol is associated
with intrinsic sympathomimetic activity (Andreka et al 2002;
Maack et al 2003). Should this be the case it might explain
the failure of bucindolol similarly to the xamoterol trial
described above.
Impressive results have been obtained with carvedilol.
The results from the US Carvedilol Heart Failure Study were
published in 1996. In this study 1064 patients with CHF
were randomized to receive either carvedilol or placebo
(Packer et al 1996). The trial was designed to evaluate the
safety of treatment with carvedilol and mortality was
observed as a secondary finding. As for the primary end
point, a significant reduction in the risk of hospitalization
was found and worsening of heart failure was reduced in
the group treated with carvedilol. A risk reduction of 65%
was found in favour of carvedilol. The problem with
interpreting the results of this study was that it was
stopped early and was a meta-analysis of a group of
studies designed to demonstrate symptomatic relief of
carvedilol. These problems became secondary with the
study of carvedilol in patients with severe heart failure.
The Carvedilol Prospective Randomized Cumulative
Survival Study (COPERNICUS) trial was performed.
2289 patients with severe heart failure were randomized
to receive carvedilol or placebo for a mean treatment
period of 10.4 months (Packer et al 2001). A decrease of
35% in risk of death was shown. The effect, previously
seen in the group with mild or moderate heart failure,Vascular Health and Risk Management 2007:3(1) 33
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was thereby reproduced in patients with severe heart
failure.
In the Carvedilol Post-Infarction Survival Control in LV
Dysfunction (CAPRICORN) study, effect of carvedilol in
patients who have had an acute myocardial infarction was
investigated (Dargie 2001). Mean Left Ventricular Ejection
Fraction (LVEF) was 32.8% and most of the patients were
already treated with both ACE-inhibitors and diuretics. A
23% reduction in all-cause mortality was seen. This
percentage in reduction is comparable with the results seen
in the large trials on ACE-inhibitors after Acute Myocardial
Infarction (AMI): SAVE (the Survival and Ventricular
Enlargement trial), AIRE (the Acute Infarction Ramipril
Efficacy study) and TRACE (the Trandolapril Cardiac
Evaluation study) (Pfeffer et al 1992; Kober et al 1995). In
spite of the result it is debated whether CAPRICORN was a
positive or a negative study. The initial primary endpoint of
this study was all-cause mortality. During the trial the
steering committee noted that all-cause mortality was lower
than expected, and they changed the primary endpoint to
the combination of all-cause mortality and all-cause
hospitalization. Eventually the original endpoint came out
positive and the new endpoint was neutral. To regulatory
authorities, CAPRICORN was therefore a negative study,
to a general scientific interpretation there are no specific
rules and many consider the trial positive.
As a net result it is widely accepted that beta-blocker
therapy has substantial benefit to patients with heart failure,
with, and without myocardial infarction. One of many
important questions that remain is whether different beta-
blockers have different value.
The first developed beta-blockers, the so-called first
generation beta-blockers, was a non-specific beta-blocker
that blocks both beta1- and beta2-adrenoceptors.
Propranolol, the traditionally used first-generation beta-
blocker, is not recommended for use in heart failure patients:
it has not been tested. Metoprolol and bisoprolol belongs to
the group of second generation beta-blockers with a specific
beta1-blockade. The third-generation beta-blockers include
carvedilol and bucindolol and have a non-selective beta-
blocking effect on both beta1- as well as beta2-
adrenoceptors. Carvedilol further has an alpha-blocking
effect which results in a vasodilating property. Bucindolol
also has a vasodilating property. The reason for the
vasodilating property of bucindolol has not clearly been
demonstrated, but it may be because of an intrinsic
sympatomimetic effect. In addition to the adrenergic
blocking properties carvedilol it has an antioxidant effect
and suppresses endothelin biosynthesis (Yue et al 1992;
Ohlstein et al 1998; Lysko et al 2000; Arumanayagam et al
2001).
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In The Carvedilol Or Metoprolol European Trial (COMET)
two generations of beta-blockers were compared.
Metoprolol, a second-generation beta-blocker was compared
with the third-generation beta-blocker carvedilol (Poole-
Wilson et al 2003). Both beta-blockers have been proven
beneficial for use in a group of patients with heart failure
(Packer et al 1996, 2001). The aim of the trial from the
outset was to study whether the extra effects of carvedilol
mattered clinically and therefore the trial was designed to
ensure as close as possible beta-1 blocking effect in the two
study groups.
3029 patients with CHF, mean ejection fraction 26%,
and NYHA II–IV , were randomized to receive metoprolol
tartrate with a target dose of 50mg twice daily or carvedilol
with a target dose of 25mg twice daily. Both beta-blockers
were well tolerated, and no differences were seen in terms
of side-effects or withdrawals (Torp-Pedersen, Poole-
Wilson, et al 2005). A significant reduction in mortality was
observed in favour of the group treated with carvedilol, with
an absolute reduction in mortality of 5.7% over a 5 year
follow-up period (Figure 1). Similarly to the reduction in
mortality, a reduction in mortality due to cardiovascular
reasons, stroke, sudden death, and death caused by
circulatory failure was seen in the group treated with
carvedilol. No differences were seen between the two groups
Figure 1 Figure 1 Figure 1 Figure 1 Figure 1 All cause mortality in the COMET trial. Copyright © 2003. Reproduced
with permission from Poole-Wilson PA, Swedberg K, Cleland JG, et al. 2003.
Comparison of carvedilol and metoprolol on clinical outcomes in patients with
chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET):
randomised controlled trial. Lancet, 362:7-13.
Abbreviations: Abbreviations: Abbreviations: Abbreviations: Abbreviations: COMET, The Carvedilol Or Metoprolol European Trial.Vascular Health and Risk Management 2007:3(1) 34
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as it comes to worsening in heart failure, hospitalizations,
and cause-specific hospitalizations (Torp-Pedersen, Poole-
Wilson, et al 2005). As an interesting finding, carvedilol
reduced the prevalence of new-onset diabetes by 22%
compared with metoprolol (Torp-Pedersen, Cleland, et al
2005). Mean duration of follow-up was 58 months, but the
benefit, in concern of reduced mortality among the patients
treated with carvedilol, appeared already at 6 months of
observation.
Much debate has been taking place since the COMET
trial was first published. Criticism has been focused on the
choice of formulation of metoprolol. In the COMET trial
immediate-release (IR) metoprolol was used instead of the
controlled-release (CR) metoprolol which was proven
beneficial in the MERIT-HF trial (MERIT-HF 1999). But
when COMET was designed in 1996, the only clinical trial
available was the Metoprolol in Dilated Cardiomyopathy
(MDC) study (Waagstein et al 1993). The question is then
whether this formulation can improve mortality and is
worthy of comparison with carvedilol. In the MDC trial,
treatment with IR metoprolol in patients with idiopathic
dilated cardiomyopathy resulted in a 34% reduction in
primary end-point, which was of all-cause mortality or need
for heart transplantation. Need for transplantation was used
as an expression for deterioration of heart failure. No
reduction in all-cause mortality was observed, possibly due
to a very low number of deaths in the trial. But when follow
up was extended a beneficial effect on mortality was indeed
observed with IR metroprolol (MDC 1998). The basic
question is, whether the apparent superior effect on mortality
seen with carvedilol compared with IR metoprolol, has any
relevance to a higher dose and more sustained blockade that
is obtained with 200mg of CR metoprolol as was used in
MERIT-HF. Was there simply insufficient beta-1 blockade
with IR metroprolol in the COMET study?
To assess the degree of beta1-blockade the most accepted
method is to study exercise-induced increase in heart rate
(HR). In a review of such studies it was found that a 20%
reduction in exercise-induced tachycardia could be obtained
with the dose of 50 mg, 100 mg and 150 mg daily with
carvedilol, IR metoprolol, and CR metoprolol respectively
(Packer 2003). In the COMET trial no evaluation of the
relative beta1-blockade of the two beta-blockers used was
performed. The only information collected was the resting
HR. A significant albeit small difference in the reduction of
HR obtained was observed in the carvedilol arm, no
difference in HR was seen beyond the first year of
observation (Figure 2) (Packer 2003). The CR metoprolol
delivers 33% less metoprolol into the bloodstream than the
IR metoprolol (Sandberg et al 1988). A significantly higher
beta1-blockade over 24 hours was seen with 200 mg of CR
metoprolol than with IR metoprolol tartrate 50 mg x 3
(Andersson et al 2001). As carvedilol exert different
adrenoceptor blocking properties besides its antioxidative
effect, it is of interest to know which mechanism gives
carvedilol its favorable effect in superiority to metoprolol
on mortality.
The alpha-blocking properties have been tested.
Doxazosin, a selective alpha1-blocker, versus placebo was
tested in 73 patients with CHF (DiBianco et al 1991). Both
investigators and patients assessment of symptomatic change
was improved after treatment with doxazosin. When
doxazosin was added to the beta1-blocker metoprolol in
patients with heart failure, no improvement in hemodynamic
measurements were seen, when compared with patients only
treated with metoprolol (Kukin et al 1996). Even though
carvedilol does not have the same pharmacokinetic
properties as the combination of doxazosin and metoprolol,
this study indicates that the beneficial effect seen with
carvedilol is less likely to be caused solely by the alpha1-
blocking properties of carvedilol.
The beta2-blocking effect affects the pre-synaptic release
of NE, which reduces the amount of NE that can stimulate
the beta1-receptors. carvedilol also exerts a more
pronounced beta1-binding, and all together this reduces the
deleterious effect of NE in heart failure (Bristow 2000).
Figure 2 Figure 2 Figure 2 Figure 2 Figure 2 Heart rate during treatment in the COMET trial. Copyright © 2003.
Reproduced with permission from Poole-Wilson PA, Swedberg K, Cleland JG, et
al. 2003. Comparison of carvedilol and metoprolol on clinical outcomes in
patients with chronic heart failure in the Carvedilol Or Metoprolol European
Trial (COMET): randomised controlled trial. Lancet, 362:7-13.
Abbreviations: Abbreviations: Abbreviations: Abbreviations: Abbreviations: COMET, The Carvedilol Or Metoprolol European Trial.
Note: Note: Note: Note: Note: *p=0.0022, †p=0.034, ‡p=0.0040.Vascular Health and Risk Management 2007:3(1) 35
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Sub-studies from the COMET trial showed a decreased
number of new-onset diabetes in the carvedilol arm, this
sub-study is published as an abstract (Torp-Pedersen,
Cleland, et al 2005). This was in contrast to earlier findings
from beta-blocker trials showing an increased number of
new-onset diabetes when treated with traditional beta1-
receptor blockers (Dahlof et al 2002). That carvedilol might
have a beneficial effects on the glucose metabolism was
already shown in a study by Jacob and colleagues (1996).
In this study metoprolol was compared with carvedilol in a
group of patients with hypertension. An improvement in
insulin sensitivity was seen among those treated with
carvedilol. Guigliano (1997) also showed improved insulin
sensitivity when treated with carvedilol. The changes were
shown by making an insulin clamp testing.
Recently a large randomized trial in which the two beta-
blockers were compared concerning their abilities in
affecting the metabolic control in patients with diabetes and
hypertension was published (Bakris et al 2004). An increase
in glycosylated hemoglobin was seen in the metoprolol arm,
whereas no change was seen in the carvedilol arm.
Improvement in insulin sensitivity was seen in the carvedilol
group and no change was seen among the patients treated
with metoprolol.
This supports the findings from the COMET trial. In
both trials the IR metoprolol was used. The beneficial role
of carvedilol is speculated to be caused by its alpha-blocking
properties and thereby causing vasodilation. Peripheral
vasodilation facilitates glucose uptake in skeletal muscle
and thereby improves insulin sensitivity (Smith and Warren
1982). Other anti-hypertensives that also increase peripheral
blood-flow have the same beneficial effect on insulin
sensitivity (Lind and Lithell 1993).
Whether the increased peripheral blood-flow is solely
to explain the benefit of carvedilol on insulin sensitivity is
doubtful. The combined effect of carvedilol, including its
antioxidative properties, is more likely to be the explanation.
Perspective of the COMET trial Perspective of the COMET trial Perspective of the COMET trial Perspective of the COMET trial Perspective of the COMET trial
The perspective of COMET can be divided in 3 parts: the
importance of beta-1 inhibition, the importance of other
effects of carvedilol and the clinical consequence.
Three beta-blockers with beta-1 activity have been
shown to reduce mortality in CHF. One interpretation of
COMET is that a more effective inhibition by carvedilol,
either because of a higher dose being given or because
carvedilol has a higher affinity for the beta-1 receptor,
explained the marked difference. Thus effective beta-1
inhibition with as high a dose as possible is clearly important
for the treatment of CHF.
The mortality difference in COMET was marked even
though the difference in resting pulse was small. Therefore,
it is likely that other effects of carvedilol compared with
metoprolol are important for the treatment of heart failure.
Further research is necessary to clarify whether beta-2
inhibition, alpha-1 inhibition, antioxidative properties of,
inhibition of endothelin-1biosynthesis, or yet another effect
is beneficial (Table 1).
As for the clinical consequence at this time what remains
is a continuing debate. carvedilol protagonists (including
the authors of this paper) will claim that a superiority of
carvedilol compared with metoprolol is likely and that this
drug should therefore be preferred for the treatment of CHF.
Metoprolol protagonists dismiss the results of COMET and
insist that a high dose of ER metoprolol should serve equal
benefit as carvedilol for patients with CHF.
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